arrow
L

Louisa R. Hoes

Netherlands Cancer Institute
H指数:13
被引数:2,251

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
2024-07-180
PRE
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy
2024-05-151
PRE
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
2024-04-171
PRE
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials
2023-07-1013
OA
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

durvalumab在错配修复缺陷或微卫星不稳定性高的实体瘤患者中的疗效,安全性和生物标志物分析

2023-03-049
OAAI
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

密码子特异性KRAS突变预测转移性结直肠癌中三氟尿苷/替匹拉西的生存益处

2023-03-0244
OAAI
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses

基于类器官药物反应的结直肠癌患者前瞻性实验治疗

2021-06-0185
OAAI
Caring for patients with cancer in the COVID-19 era (vol 26, pg 665, 2020)
2020-06-038
OAAI